Literature DB >> 10772639

Dose-dependent pharmacokinetics of cyclosporin A in rats: events in tissues.

C Tanaka1, R Kawai, M Rowland.   

Abstract

Cyclosporin A (CyA) tissue distribution kinetics was extensively studied after single 1.2-, 6-, and 30-mg/kg CyA doses (via 2-min i.v. infusion) to rats. Drug concentrations in blood and various tissues were measured using a specific radioimmunoassay. Based on total blood concentration data alone, CyA systemic pharmacokinetics appeared essentially linear. However, after taking the saturable, nonlinear blood cell binding into account, multiple nonlinear factors were identified. Intrinsic clearance at 30 mg/kg was about half the value at the two lower doses. Tissue distribution was also dose-dependent, with evidence of saturable binding in many tissues. In general, blood binding saturation (dissociation constant K(D) = 0. 18 microg/ml) occurred at a lower dose (concentration) than saturation of tissue binding (K(D), 0.005-0.77 microg/g), such that the volume of distribution at steady state first increased as the dose increased from 1.2 to 6 mg/kg, and then decreased as the dose increased to 30 mg/kg. Tissue binding was further investigated by various graphical analyses. Some organs showed a monophasic (single site) Scatchard plot of the tissue data at steady state, with high K(D) values. In other organs, biphasic binding characteristics were observed with the K(D) values of the high-affinity site in the same range as the K(D) reported for the binding of CyA with cyclophilin, the putative target. Saturable tissue binding may therefore influence not only the pharmacokinetics but also the efficacy of CyA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10772639

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  20 in total

1.  Novel in vitro-in vivo extrapolation (IVIVE) method to predict hepatic organ clearance in rat.

Authors:  Ken-ichi Umehara; Gian Camenisch
Journal:  Pharm Res       Date:  2011-10-20       Impact factor: 4.200

2.  Physiologically based pharmacokinetics of cyclosporine A: reevaluation of dose-nonlinear kinetics in rats.

Authors:  C Tanaka; R Kawai; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1999-12

Review 3.  Dose selection based on physiologically based pharmacokinetic (PBPK) approaches.

Authors:  Hannah M Jones; Kapil Mayawala; Patrick Poulin
Journal:  AAPS J       Date:  2012-12-27       Impact factor: 4.009

4.  Insights into the effects of hyperlipoproteinemia on cyclosporine A biodistribution and relationship to renal function.

Authors:  Hamidreza Montazeri Aliabadi; Tara J Spencer; Parvin Mahdipoor; Afsaneh Lavasanifar; Dion R Brocks
Journal:  AAPS J       Date:  2006-10-27       Impact factor: 4.009

5.  Modelling and PBPK simulation in drug discovery.

Authors:  Hannah M Jones; Iain B Gardner; Kenny J Watson
Journal:  AAPS J       Date:  2009-03-12       Impact factor: 4.009

6.  A modified coumarinic acid-based cyclic prodrug of an opioid peptide: its enzymatic and chemical stability and cell permeation characteristics.

Authors:  Hui Ouyang; Fuxing Tang; Teruna J Siahaan; Ronald T Borchardt
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

7.  Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa?

Authors:  Fuxing Tang; Kazutoshi Horie; Ronald T Borchardt
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

8.  Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa?

Authors:  Fuxing Tang; Kazutoshi Horie; Ronald T Borchardt
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

Review 9.  Physiologically-based PK/PD modelling of therapeutic macromolecules.

Authors:  Peter Thygesen; Panos Macheras; Achiel Van Peer
Journal:  Pharm Res       Date:  2009-10-22       Impact factor: 4.200

10.  Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential.

Authors:  Michael Gertz; Catherine M Cartwright; Michael J Hobbs; Kathryn E Kenworthy; Malcolm Rowland; J Brian Houston; Aleksandra Galetin
Journal:  Pharm Res       Date:  2012-11-22       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.